Proathlete Wealth Management’s Biogen BIIB Stock Holding History

Proathlete Wealth Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$229K	Sell	1,060 -884	-45%	-$169K	0.06%	61
2026 Q1	$356K	Sell	1,944 -164	-8%	-$30.2K	0.1%	49
2025 Q4	$371K	Buy	2,108 +40	+2%	+$6.54K	0.1%	48
2025 Q3	$290K	Sell	2,068 -1	-0%	-$135	0.08%	49
2025 Q2	$260K	Buy	2,069 +2	+0.1%	+$249	0.08%	52
2025 Q1	$283K	Buy	2,067 +223	+12%	+$31.9K	0.1%	51
2024 Q4	$282K	Hold	1,844	–	–	0.11%	51
2024 Q3	$357K	Hold	1,844	–	–	0.15%	48
2024 Q2	$427K	Sell	1,844 -69	-4%	-$15K	0.2%	43
2024 Q1	$413K	Sell	1,913 -11	-0.6%	-$2.58K	0.22%	43
2023 Q4	$498K	Buy	+1,924	New	+$473K	0.29%	42

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Proathlete Wealth Management's BIIB Position: Q2 2026 in Review

Proathlete Wealth Management reduced its Biogen (BIIB) stake by 45% in Q2 2026, selling an estimated $169K and leaving 1,060 shares worth $229K. The position accounts for 0.06% of the portfolio, ranked #61.

Proathlete Wealth Management first reported a position in BIIB in Q4 2023 and has held it in 11 quarters since. The position peaked at $498K in Q4 2023. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Proathlete Wealth Management held 1,060 shares of Biogen worth $229K as of Q2 2026.
Proathlete Wealth Management sold 884 Biogen shares in Q2 2026, an estimated $169K.
Biogen made up 0.06% of Proathlete Wealth Management's portfolio in Q2 2026, its #61 holding.
Proathlete Wealth Management first reported a position in Biogen in Q4 2023 and has held it in 11 quarters since.
Proathlete Wealth Management's Biogen position peaked at $498K in Q4 2023.
1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Proathlete Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.